Neolacta Lifesciences Est Profile
Key Indicators
- Authorised Capital ₹ 1.60 Cr
as on 21-12-2024
- Paid Up Capital ₹ 1.60 Cr
as on 21-12-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 59.99%
(FY 2022)
- Profit 850.51%
(FY 2022)
- Ebitda 618.19%
(FY 2022)
- Net Worth 68.39%
(FY 2022)
- Total Assets 19.51%
(FY 2022)
About Neolacta Lifesciences Est
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.60 Cr and a paid-up capital of Rs 1.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Joshi Madhu and Saurabh Aggarwal serve as directors at the Company.
- CIN/LLPIN
U15200KA2016PTC092341
- Company No.
092341
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Neolacta Lifesciences Est Private Limited offer?
Neolacta Lifesciences Est Private Limited offers a wide range of products and services, including Baby Care, Baby Food.
Who are the key members and board of directors at Neolacta Lifesciences Est?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Joshi Madhu  | Director | 11-Sep-2020 | Current |
Saurabh Aggarwal  | Director | 12-Apr-2016 | Current |
Financial Performance of Neolacta Lifesciences Est.
Neolacta Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 59.99% increase. The company also saw a substantial improvement in profitability, with a 850.51% increase in profit. The company's net worth Soared by an impressive increase of 68.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neolacta Lifesciences Est?
In 2022, Neolacta Lifesciences Est had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neolacta Lifesciences Est?
Neolacta Lifesciences Est has a workforce of 68 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neolacta Lifesciences Est, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neolacta Lifesciences Est's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
